PITTSBURGH, April 8, 2008 /PRNewswire/ -- Precision Therapeutics Inc., a leader in personalized medicine, said today it signed contracts with National Preferred Provider Network (NPPN), PlanCare America (PCA), RMSCO, and SEIBA Inc.
NPPN, headquartered in Middletown, NY, is one of the largest PPO networks in the country representing more than seven million lives. Their list of clients includes multi-state companies, Fortune 500 companies, federal organizations, and regional employers. NPPN providers include Memorial Sloan-Kettering Cancer Center, North Shore Health Systems in New York, Quest Diagnostics and Brown and Toland in San Francisco.
PCA, located in Atlanta, GA, is a national network of healthcare providers representing over a million lives. Their panel of directly contracted providers includes independent physicians, medical group practices, specialty facilities, acute care hospitals, and ancillary medical providers. PCA has relationships with over 300 payors and 12,000 employers nationwide. Payors include Taft Hartley Funds, Self Funded Groups, Insurance Companies, Third Party Administrators, and HMOs.
SIEBA, LTD, located in Endicott, NY, links the delivery of services to the employer community in the Northeast Region of the US. SIEBA's focus is providing unparalleled third party administrative services for employee benefits in both public and private sectors in the Northeast.
Established in 1981, RMSCO is now one of the largest multi-line Third-Party Administrators in the Northeast. RMSCO, headquartered in Liverpool, NY provides services to over 200 clients representing over 200,000 individuals in all 50 states.
"Precision Therapeutics is pleased to add these organizations to our growing list of payor organizations under contract. Contracting with these leading organizations expands the number of covered lives, thus allowing our technology to be available to more patients and allowing for faster reimbursement of claims," said Precision CEO Sean McDonald.
About Precision Therapeutics
Precision Therapeutics is a diagnostics services company dedicated to providing physicians, patients, and payors with information to personalize cancer treatment. Precision's ChemoFx(R) test, based on a proprietary live tumor cell-based platform, measures an individual patient's tumor sensitivity and resistance to a clinically relevant range of therapeutic alternatives under consideration by the physician. Since introduction, over 5,000 ChemoFx tests have been performed commercially in over 30 different types of solid tumors. For more information visit http://www.precisiontherapeutics.com, call 800-547-6165 or email firstname.lastname@example.org.
|SOURCE Precision Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved